Supplementary Information

Insertion of N-tosylacetimidates/acetimidamides onto arynes via [2+2] cycloaddition

Ramagonolla Kranthikumar, Rambabu Chegondi and Srivari Chandrasekhar*


Division of Natural Product Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India.

E-mail: srivaric@iict.res.in


	Pages
1. ¹ H NMR, ¹³ C NMR spectra	S-2 to S-41
2. X-ray crystallographic data	S42 to S-44

Ethyl (Z)-2-phenyl-N-tosylacetimidate (2a):

(¹H NMR, CDCl₃, 300 MHz)




(13C NMR, CDCl₃, 400 MHz)




Ethyl (E)-2-(o-tolyl)-N-tosylacetimidate (2b):


(¹H NMR, CDCl₃, 500 MHz)



Ethyl (E)-2-(3,4-dimethoxyphenyl)-N-tosylacetimidate (2c):




 $(^{1}HNMR, CDCl_{3}, 500 MHz)$




Ethyl (E)-2-([1,1'-biphenyl]-4-yl)-N-tosylacetimidate (2d):

(¹H NMR, CDCl₃, 400 MHz)




Ethyl (E)-2-(3-chlorophenyl)-N-tosylacetimidate (2e):

(¹H NMR, CDCl₃, 400 MHz)




CI (¹³C NMR, CDCl₃, 300 MHz)




Ethyl (E)-2-(2-bromophenyl)-N-tosylacetimidate (2f):

(¹H NMR, CDC₃, 400 MHz)




Methyl (E)-(2-phenyl-1-(tosylimino)ethyl)glycinate (2g):


 $(^{1}H NMR, CDC_{3}, 500 MHz)$




Methyl (E)-(2-phenyl-1-(tosylimino)ethyl)-L-alaninate (2h):

(¹H NMR, CDCl₃, 300 MHz)






(13C NMR, CDCl₃, 75 MHz)





Methyl (E)-(2-phenyl-1-(tosylimino)ethyl)-L-valinate (2i):

(¹H NMR, CDCl₃, 500 MHz)




$\label{eq:methyl} \begin{tabular}{ll} Methyl (S,E)-2-phenyl-2-(2-phenyl-N'-tosylacetimidamido) acetate (2j): \\ \end{tabular}$






Ethyl (*Z*)-2-benzyl-*N*-tosylbenzimidate (3a):

(¹H NMR, CDCl₃, 400 MHz)




Ethyl (Z)-2-(2-methylbenzyl)-N-tosylbenzimidate (3b):

 $(^{1}HNMR, CDCl_{3}, 500 MHz)$




Ethyl (*Z*)-2-(3,4-dimethoxybenzyl)-*N*-tosylbenzimidate (3c):


(¹H NMR, CDCl₃, 500 MHz)









Ethyl (*Z*)-2-(3-chlorobenzyl)-*N*-tosylbenzimidate (3e):







Ethyl (Z)-2-(2-bromobenzyl)-N-tosylbenzimidate (3f):




Methyl (Z)-((2-benzylphenyl)(tosylimino)methyl)glycinate (3g):




Methyl (Z)-((2-benzylphenyl)(tosylimino)methyl)-L-alaninate (3h):






Methyl (Z)-((2-benzylphenyl)(tosylimino)methyl)valinate (3i):




Methyl (S,Z)-2-(2-benzyl-N'-tosylbenzimidamido)-2-phenylacetate (3j):




Ethyl (Z)-6-([1,1'-biphenyl]-4-ylmethyl)-N-tosylbenzo[d][1,3]dioxole-5-carbimidate (3k):

 $(^{1}H\,NMR,\,CDCl_{3},\,500\,MHz)$



$\label{lem:eq:continuous} \mbox{Ethyl (Z)-6-(3-chlorobenzyl)-N-tosylbenzo[d][1,3] dioxole-5-carbimidate (3l):}$


 $^{1}\mathrm{H}\,\mathrm{NMR},\,\mathrm{CDCl_{3}},\,500\mathrm{MHz}$



Ethyl (*Z*)-2-benzyl-4,6-dimethoxy-*N*-tosylbenzimidate (3m):




(¹H NMR, CDCl₃, 300 MHz)




Ethyl (Z)-2,4-dimethoxy-6-(2-methylbenzyl)-N-tosylbenzimidate (3n):


(¹H NMR, CDCI₃, 300 MHz)





Ethyl (Z)-2-(3,4-dimethoxybenzyl)-4,6-dimethoxy-N-tosylbenzimidate (30):




(¹H NMR, CDCl₃, 500 MHz)









Ethyl (Z)-2-(3-chlorobenzyl)-4,6-dimethoxy-N-tosylbenzimidate (3q):







Ethyl (Z)-2-benzyl-4,5-dimethyl-N-tosylbenzimidate (3r):




Ethyl (Z)-2-(3-chlorobenzyl)-4,5-dimethyl-N-tosylbenzimidate (3s):






Ethyl 2-benzylbenzoate (4):

(¹H NMR, CDCl₃, 300 MHz)




2-Benzyl-*N*-tosylbenzamide (5):

(¹H NMR, CDCl₃, 400 MHz)




Ethyl 2-benzoylbenzoate (6):

 $(^{1}H NMR, CDC_{3}, 500 MHz)$





2-Benzylbenzaldehyde (7):

 $(^{1}H NMR, CDC_{3}, 500 MHz)$




${\it N}\hbox{-}(1\hbox{-}{\bf Allyl}\hbox{-}3\hbox{-}{\bf phenyl}\hbox{-}1\hbox{H-indol-}2\hbox{-}{\bf yl})\hbox{-}4\hbox{-}{\bf methyl}\hbox{-}N\hbox{-}{\bf phenyl}{\bf benzenesulfonamide}\ (9a):$






(Z)-N-(5-Allyl-5,11-dihydro-6H-dibenzo[b,e]azepin-6-ylidene)-4-methylbenzenesulfonamide (10a):


 $(^{1}H NMR, CDCl_{3}, 400 MHz)$




4-Methyl- N- (1-methyl-3-phenyl-1H-indol-2-yl)- N- phenylbenzene sulfonamide (9b):




(Z)-4-methyl-N-(5-methyl-5,11-dihydro-6H-dibenzo[b,e]azepin-6-ylidene)benzenesulfonamide (10b):




N-(1-allyl-3-(phenyl-2-d)-1H-indol-2-yl)-4-methyl-N-(phenyl-2-d) benzenesul fon a mide (11):




(¹H NMR, CDCl₃, 500 MHz)





HRMS Spectrum for compound 11:



Ethyl (Z)-N-tosylhexanimidate (S1):







3. X-ray crystallographic data

X-ray data for the compounds (BB44 and BB45) were collected at room temperature using a Bruker Smart Apex CCD diffractometer with graphite monochromated MoK α radiation (λ =0.71073Å) with ω -scan method [1]. Preliminary lattice parameters and orientation matrices were obtained from four sets of frames.

Integration and scaling of intensity data was accomplished using SAINT program [1]. The structure was solved by direct methods using SHELXS [2] and refinement was carried out by full-matrix least-squares technique using SHELXL [2]. Anisotropic displacement parameters were included for all non-hydrogen atoms. All H atoms were positioned geometrically and treated as riding on their parent C atoms with $U_{iso}(H)$ 1.2 $U_{eq}(C)$. The atom C30 of BB44 shows high thermal parameter hence it was restrained with SIMU and DFIX commands (SHELXL, [2]).

a. Compound 3q (BB45):




Figure 1. ORTEP of compound 3q

Figure 1. A view of BB45, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are represented by circles of arbitrary radii.

Crystal Data for BB45: $C_{25}H_{26}NO_5SC1$ (M=487.98): monoclinic, space group $P2_1/c$ (no. 14), a =17.7060(4) Å, b = 14.3230(6) Å, c = 9.7000(8) Å, $\beta = 104.923(2)^{\circ}$, V = 2377.0(2) Å³, Z = 4, $T = 104.923(2)^{\circ}$ 294.15 K, μ (MoKα) = 0.285 mm⁻¹, Dcalc = 1.364 g/mm³, 26482 reflections measured (2.38 \leq 2Θ \leq 56.65), 5704 unique ($R_{\text{int}} = 0.0289$) which were used in all calculations. The final R_1 was 0.0552 (I > $2\sigma(I)$) and wR_2 was 0.1463 (all data). CCDC 1435198 contains supplementary Crystallographic data for the structure. These data can be obtained free of charge www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033; email: deposit@ccdc.cam.ac.uk].

b. Compound 9a (BB44):




Figure 2. ORTEP of compound 9a

Figure 2. A view of BB44, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are represented by circles of arbitrary radii

Crystal Data for BB44: $C_{30}H_{26}N_2O_2S$ (M =478.59): triclinic, space group P-1 (no. 2), a = 10.1720(5) Å, b = 10.4620(5) Å, c = 12.8780(6) Å, α = 68.8240(10)°, β = 83.9450(10)°, γ = 83.7910(10)°, V = 1267.17(11) ų, Z = 2, T = 294.15 K, μ (MoK α) = 0.157 mm⁻¹, Dcalc = 1.254 g/mm³, 14981 reflections measured (3.4 \leq 2 Θ \leq 56.554), 5952 unique (R_{int} = 0.0199) which were used in all calculations. The final R_1 was 0.0504 (I > 2 σ (I)) and wR_2 was 0.1424 (all data). CCDC 1435197 contains supplementary Crystallographic data for the structure.

- Bruker (2001). SAINT (Version 6.28a) & SMART (Version 5.625). Bruker AXS Inc., Madison, Wisconsin, USA.
- 2. Sheldrick G. M. (2015) Acta Crystallogr C71: 3-8.